Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | THRA | P10827 | 3/20 | 0.54 |
| ▸ | THRB | P10828 | 3/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.47 |
| ▸ | RARB | P10826 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16050407 | 0.98 | ALDH1A1 (0.70) | GPR84ALDH1A1HPGDHSD17B10THRA | |
| SCHEMBL22040784 | 0.98 | ALDH1A1 (0.70) | GPR84ALDH1A1HPGDHSD17B10THRA | |
| SCHEMBL28049655 | 0.98 | GPR84 (0.70) | GPR84ALDH1A1HPGDHSD17B10THRA | |
| SCHEMBL28161011 | 0.96 | GPR84 (0.68) | GPR84ALDH1A1HPGDHSD17B10THRA | |
| SCHEMBL290207 | 0.93 | PTGS2 (0.67) | GPR84ALDH1A1HPGDHSD17B10THRA | |
| SCHEMBL16050465 | 0.91 | GPR84 (0.62) | GPR84ALDH1A1HPGDHSD17B10THRA | |
| Setogepram SCHEMBL29395927 | 0.85 | ALDH1A1 (0.69) | GPR84ALDH1A1HPGDHSD17B10PPARA | |
| Setogepram SCHEMBL289216 | 0.85 | ALDH1A1 (0.69) | GPR84ALDH1A1HPGDHSD17B10PPARA | |
| SCHEMBL17678363 | 0.85 | GPR84 (0.73) | GPR84ALDH1A1HPGDHSD17B10PTGS2 | |
| SCHEMBL846163 | 0.84 | ALDH1A1 (1.00) | ALDH1A1HPGDHSD17B10PTGS2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550066-B2 | Substituted aromatic compounds and related method for the treatment of fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2020-02-04 | — | — | US | claimed |
| US-11524930-B2 | Substituted aromatic compounds and related method for the treatment of fibrosis | Liminal Biosciences Limited (GB) | 2022-12-13 | — | — | US | disclosed |
| US-11524930-B2 | Substituted aromatic compounds and related method for the treatment of fibrosis | Liminal Biosciences Limited (GB) | 2022-12-13 | — | — | US | disclosed |
| CN-110105200-B | Substituted aromatic compounds for treating fibrosis and related methods | 里米诺生物科学有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | Liminal Biosciences Limited (GB) | 2021-11-30 | — | — | US | disclosed |
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | LIMINAL BIOSCIENCES LTD (GB) | 2021-03-25 | — | — | US | disclosed |
| EP-3203998-B1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETES | LIMINAL BIOSCIENCES LTD (GB) | 2021-03-10 | — | — | EP | disclosed |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | Liminal Biosciences Limited (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20200237693-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | LIMINAL BIOSCIENCES INC (GB) | 2020-07-30 | — | — | US | disclosed |
| US-20200172462-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND RELATED METHOD FOR THE TREATMENT OF FIBROSIS | Liminal Biosciences Limited (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20170209399-A1 | Substituted Aromatic Compounds and Pharmaceutical Compositions For The Prevention And Treatment Of Diabetes | PROMETIC PHARMA SMT LIMITED (GB) | 2017-07-27 | — | — | US | disclosed |
| WO-2016074068-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | PROMETIC BIOSCIENCES INC. (CA) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016054728-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016054726-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETES | PROMETIC BIOSCIENCES INC. (CA) | 2016-04-14 | — | — | WO | disclosed |
| US-20160039736-A1 | Substituted Aromatic Compounds and Related Method for the Treatment of Fibrosis | Liminal Biosciences Limited (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20160039736-A1 | Substituted Aromatic Compounds and Related Method for the Treatment of Fibrosis | Liminal Biosciences Limited (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20160039736-A1 | Substituted Aromatic Compounds and Related Method for the Treatment of Fibrosis | Liminal Biosciences Limited (GB) | 2016-02-11 | — | — | US | disclosed |
| EP-2970089-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND RELATED METHOD FOR THE TREATMENT OF FIBROSIS | ProMetic BioSciences Inc. (CA) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014138906-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND RELATED METHOD FOR THE TREATMENT OF FIBROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014138906-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND RELATED METHOD FOR THE TREATMENT OF FIBROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | COL1A1, CCNH, COL2A1 | GPR84 1983/4885ALDH1A1 129/4885HPGD 580/4885 |
| US-20200237693-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ADIPOR1, ADIPOR2, FN1 | GPR84 632/4885ALDH1A1 1129/4885HPGD 2307/4885 |
| US-11524930-B2 | Substituted aromatic compounds and related method for the treatment of fibrosis | CFH, C5, C9 | GPR84 1802/4885ALDH1A1 640/4885HPGD 2870/4885 |
| US-20200172462-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND RELATED METHOD FOR THE TREATMENT OF FIBROSIS | CFH, C5, C9 | GPR84 1652/4885ALDH1A1 808/4885HPGD 2912/4885 |
| US-10550066-B2 | Substituted aromatic compounds and related method for the treatment of fibrosis | CFH, C9, C5 | GPR84 1762/4885ALDH1A1 742/4885HPGD 2944/4885 |
| US-20160039736-A1 | Substituted Aromatic Compounds and Related Method for the Treatment of Fibrosis | CFH, C9, C5 | GPR84 2045/4885ALDH1A1 699/4885HPGD 3060/4885 |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | COL1A1, CCNH, COL2A1 | GPR84 1983/4885ALDH1A1 129/4885HPGD 580/4885 |
| US-20170209399-A1 | Substituted Aromatic Compounds and Pharmaceutical Compositions For The Prevention And Treatment Of Diabetes | GPR119, LIPC, INSR | GPR84 1382/4885ALDH1A1 1302/4885HPGD 3062/4885 |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | ADIPOR1, ADIPOR2, FN1 | GPR84 632/4885ALDH1A1 1129/4885HPGD 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.